Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes (T2D) is a very prevalent, multisystemic, chronic metabolic disorder closely related to atherosclerosis and cardiovascular diseases. It is characterised by mitochondrial dysfunction and the presence of oxidative stress. Metformin is one of the safest and most effective anti-hyperglycaemic agents currently employed as first-line oral therapy for T2D. It has demonstrated additional beneficial effects, unrelated to its hypoglycaemic action, on weight loss and several diseases, such as cancer, cardiovascular disorders and metabolic diseases, including thyroid diseases. Despite the vast clinical experience gained over several decades of use, the mechanism of action of metformin is still not fully understood. This review provides an overview of the existing literature concerning the beneficial mitochondrial and vascular effects of metformin, which it exerts by diminishing oxidative stress and reducing leukocyte-endothelium interactions. Specifically, we describe the molecular mechanisms involved in metformin's effect on gluconeogenesis, its capacity to interfere with major metabolic pathways (AMPK and mTORC1), its action on mitochondria and its antioxidant effects. We also discuss potential targets for therapeutic intervention based on these molecular actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“the activation of AMPK through the energetic dysbalance (increased AMP/ATP ratio), metformin has been reported to activate AMPK by increasing phosphorylation of the AMPK catalytic α subunit at Thr172 in primary hepatocytes [112].”
BackgroundNormalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277 · cited 1×
“tissue, but under hyperglycaemic conditions, glucose can be shunted to other locations, leading to the generation of AGEs or activation of the polyol pathway [63].”
BackgroundDysfunction of Mitochondria in Human Skeletal Muscle in Type 2 Diabetes
Kelley, D. E., He, J., Menshikova, E. V., & Ritov, V. B. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2944 · Cited by 2,321
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
Mitochondrial dysfunction in the elderly: possible role in insulin resistance
Petersen, K. F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D. L., DiPietro, L., Cline, G. W., & Shulman, G. I. (2003) · Science · doi:10.1126/science.1082889 · Cited by 2,107 · cited 1×
“uptake [4], and several related comorbidities, including cardiovascular diseases (CVD) [5].”
BackgroundThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Kim, J.-A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006) · Circulation · doi:10.1161/circulationaha.105.563213 · Cited by 1,652
Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Exercise, GLUT4, and skeletal muscle glucose uptake
Richter, E. A., & Hargreaves, M. (2013) · Physiological Reviews · doi:10.1152/physrev.00038.2012 · Cited by 1,407
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 2×
“Other consequences of the respiratory chain inhibition besides ATP production, such as changes in the NAD/NADH ratio, may also contribute to the effects of metformin on gluconeogenesis [119].”
BackgroundPrognostic Value of Coronary Vascular Endothelial Dysfunction
Halcox, J. P. J., Schenke, W. H., Zalos, G., Mincemoyer, R., Prasad, A., Waclawiw, M. A., Nour, K. R. A., & Quyyumi, A. A. (2002) · Circulation · doi:10.1161/01.cir.0000025404.78001.d8 · Cited by 1,385 · cited 10×
“Despite its presence on the market for six decades now, this compound continues to intrigue researchers, especially due to mounting evidence of its effectiveness in other metabolic pathologies, such as obesity, PCOS [71], CVD [72], non-alcoholic fatty liver disease [73], premature puberty [74], kidney disease [75], T1…”
BackgroundInfluentialCeriello, A., & Motz, E. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000122852.22604.78 · Cited by 1,378
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 2×
“Some studies suggest that complex I is only affected by high, supratherapeutic concentrations of metformin [123].”
BackgroundForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 3×
“Despite the abundant bibliography that support the implication of AMPK, there is still controversy surrounding the absolute requirement of AMPK for metformin-induced suppression of glucose production [111], with the number of reports of the AMPK-independent actions of metformin increasing over the years [87].”
BackgroundCusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M. E., Pratipanawatr, T., DeFronzo, R. A., Kahn, C. R., & Mandarino, L. J. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7535 · Cited by 1,139 · cited 1×
“different animal models of IR and humans [33].”
BackgroundMetformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
Wheaton, W. W., Weinberg, S. E., Hamanaka, R. B., Soberanes, S., Sullivan, L. B., Anso, E., Glasauer, A., Dufour, E., Mutlu, G. M., Budigner, G. S., et al. (2014) · eLife · doi:10.7554/elife.02242 · Cited by 1,105
Mitophagy: mechanisms, pathophysiological roles, and analysis
Ding, W.-X., & Yin, X.-M. (2012) · bchm · doi:10.1515/hsz-2012-0119 · Cited by 1,032
Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism
Cabreiro, F., Au, C., Leung, K.-Y., Vergara-Irigaray, N., Cochemé, H. M., Noori, T., Weinkove, D., Schuster, E., Greene, N. D. E., & Gems, D. (2013) · Cell · doi:10.1016/j.cell.2013.02.035 · Cited by 967
Schmidt, A. M., Hori, O., Chen, J. X., Li, J. F., Crandall, J., Zhang, J., Cao, R., Yan, S. D., Brett, J., & Stern, D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118175 · Cited by 896
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Morino, K. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25151 · Cited by 811 · cited 1×
“Importantly, ROS production can modify signals that activate the serine kinases that phosphorylate IRS proteins [34].”
BackgroundAnti-inflammatory effects of metformin irrespective of diabetes status
Cameron, A. R., Morrison, V. L., Levin, D., Mohan, M., Forteath, C., Beall, C., McNeilly, A. D., Balfour, D. J. K., Savinko, T., Wong, A. K. F., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308445 · Cited by 704 · cited 1×
“Metformin has also been shown to have direct effects on inflammation [107]; it acts on NF-κB signalling and differentiation of monocytes into macrophages [108] and is able to suppress several inflammatory cytokines in the plasma of non-diabetic individuals [109].”
BackgroundEffects of metformin and other biguanides on oxidative phosphorylation in mitochondria
Bridges, H. R., Jones, A. J. Y., Pollak, M. N., & Hirst, J. (2014) · Biochemical Journal · doi:10.1042/bj20140620 · Cited by 661 · cited 1×
“While some suggest that it does not competitively bind to the ubiquinone-binding site in complex I [121], others point to the 49 kDa subunit containing the ubiquinone binding site on the matrix side as the location of guanidine binding [122].”
BackgroundMoiseeva, O., Deschênes‐Simard, X., St‐Germain, E., Igelmann, S., Huot, G., Cadar, A. E., Bourdeau, V., Pollak, M. N., & Ferbeyre, G. (2013) · Aging Cell · doi:10.1111/acel.12075 · Cited by 654
Markers of Oxidative Stress during Diabetes Mellitus
Tiwari, B. K., Pandey, K. B., Abidi, A. B., & Rizvi, S. I. (2013) · Journal of Biomarkers · doi:10.1155/2013/378790 · Cited by 517 · cited 2×
“metabolism, including retinopathy, neuropathy, nephropathy, vascular diseases and cardiomyopathy [23].”
BackgroundImproved Endothelial Function With Metformin in Type 2 Diabetes Mellitus
Mather, K. J., Verma, S., & Anderson, T. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01129-9 · Cited by 513
Metformin pathways: pharmacokinetics and pharmacodynamics
Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283559b22 · Cited by 495
Xie, Z., Lau, K., Eby, B., Lozano, P., He, C., Pennington, B., Li, H., Rathi, S., Dong, Y., Tian, R., et al. (2011) · Diabetes · doi:10.2337/db10-0351 · Cited by 490 · cited 1×
“various metabolic and cellular processes, such as autophagy [103,104] and cellular senescence [105,106], which are closely linked to the development of age-related conditions.”
BackgroundMetformin and inflammation: its potential Beyond glucose-lowering effect
Saisho, Y. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150316124019 · Cited by 450 · cited 1×
“Metformin has also been shown to have direct effects on inflammation [107]; it acts on NF-κB signalling and differentiation of monocytes into macrophages [108] and is able to suppress several inflammatory cytokines in the plasma of non-diabetic individuals [109].”
BackgroundKim, Y. D., Park, K.-G., Lee, Y.-S., Park, Y.-Y., Kim, D.-K., Nedumaran, B., Jang, W. G., Cho, W.-J., Ha, J., Lee, I.-K., et al. (2008) · Diabetes · doi:10.2337/db07-0381 · Cited by 422
Regulation of Insulin Action by Ceramide
Stratford, S., Hoehn, K. L., Liu, F., & Summers, S. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406499200 · Cited by 410 · cited 4×
“Activation of PKCβ1/2 activation via diacylglycerol can alter different proteins in the altering hemodynamics, vascular permeability, vascular endothelium growth factor (VEGF) production and redox signaling in the vessels [64].”
BackgroundInfluentialMetformin Activates a Duodenal Ampk-Dependent Pathway to Lower Hepatic Glucose Production in Rats
Duca, F. A., Côté, C. D., Rasmussen, B. A., Zadeh-Tahmasebi, M., Rutter, G. A., Filippi, B. M., & Lam, T. K. T. (2015) · Nature Medicine · doi:10.1038/nm.3787 · Cited by 402 · cited 1×
“crosstalk has been identified in rats linking intestinal metformin exposure to the suppression of hepatic glucose production via the nucleus tractus solitarius and nervus vagus efferents through AMPK and GLP-1 receptor activation [100].”
BackgroundVasamsetti, S. B., Karnewar, S., Kanugula, A. K., Thatipalli, A. R., Kumar, J. M., & Kotamraju, S. (2015) · Diabetes · doi:10.2337/db14-1225 · Cited by 397 · cited 1×
“Metformin has also been shown to have direct effects on inflammation [107]; it acts on NF-κB signalling and differentiation of monocytes into macrophages [108] and is able to suppress several inflammatory cytokines in the plasma of non-diabetic individuals [109].”
BackgroundWang, Q., Zhang, M., Torres, G., Wu, S., Ouyang, C., Xie, Z., & Zou, M.-H. (2017) · Diabetes · doi:10.2337/db16-0915 · Cited by 370 · cited 2×
“function, endothelial function, and leukocyte-endothelium interactions may be key to preventing the vascular damage and development of an atherogenic process in T2D [159,160].”
BackgroundMetformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2
De Haes, W., Frooninckx, L., Van Assche, R., Smolders, A., Depuydt, G., Billen, J., Braeckman, B. P., Schoofs, L., & Temmerman, L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321776111 · Cited by 355 · cited 1×
“There is a growing body of evidence showing that metformin can increase healthy lifespan in vivo in nematodes [80,81] and mice [82,83].”
BackgroundMetformin slows down aging and extends life span of female SHR mice
Anisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Tyndyk, M. L., Yurova, M. V., Kovalenko, I. G., Poroshina, T. E., et al. (2008) · Cell Cycle · doi:10.4161/cc.7.17.6625 · Cited by 348
Pharmacokinetics of Metformin After Intravenous and Oral Administration to Man
Pentik�inen, P. J., Neuvonen, P. J., & Penttil�, A. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562061 · Cited by 348
Kiritoshi, S., Nishikawa, T., Sonoda, K., Kukidome, D., Senokuchi, T., Matsuo, T., Matsumura, T., Tokunaga, H., Brownlee, M., & Araki, E. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2570 · Cited by 345
Song, Y. M., Lee, Y.-H., Kim, J.-W., Ham, D.-S., Kang, E.-S., Cha, B. S., Lee, H. C., & Lee, B.-W. (2015) · Autophagy · doi:10.4161/15548627.2014.984271 · Cited by 332
Free radicals and muscle fatigue: of ROS, canaries, and the IOC
Reid, M. B. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.03.002 · Cited by 329
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
LI, Y., LIU, L., WANG, B., WANG, J., & CHEN, D. (2013) · Biomedical Reports · doi:10.3892/br.2012.18 · Cited by 290
Anisimov, V. N., Berstein, L. M., Popovich, I. G., Zabezhinski, M. A., Egormin, P. A., Piskunova, T. S., Semenchenko, A. V., Tyndyk, M. L., Yurova, M. N., Kovalenko, I. G., et al. (2011) · Aging · doi:10.18632/aging.100273 · Cited by 285
Host-microbe-drug-nutrient screen identifies bacterial effectors of metformin therapy
Pryor, R., Norvaisas, P., Marinos, G., Best, L., Thingholm, L. B., Quintaneiro, L. M., De Haes, W., Esser, D., Waschina, S., Lujan, C., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.003 · Cited by 274
Lai, Y.-C., Tabima, D. M., Dube, J. J., Hughan, K. S., Vanderpool, R. R., Goncharov, D. A., St. Croix, C. M., Garcia-Ocaña, A., Goncharova, E. A., Tofovic, S. P., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.018935 · Cited by 270 · cited 1×
“tivity promotes antioxidant effects in the cell and normalizes pulmonary hypertension associated with heart failure involving preserved ejection fraction [154].”
BackgroundMetformin-induced mitochondrial Complex I inhibition: facts, uncertainties, and consequences
Fontaine, E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00753 · Cited by 269
Metformin modulates hyperglycaemia‐induced endothelial senescence and apoptosis through SIRT1
Arunachalam, G., Samuel, S. M., Marei, I., Ding, H., & Triggle, C. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12496 · Cited by 221
Nesti, L., & Natali, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.04.009 · Cited by 211 · cited 10×
“Despite its presence on the market for six decades now, this compound continues to intrigue researchers, especially due to mounting evidence of its effectiveness in other metabolic pathologies, such as obesity, PCOS [71], CVD [72], non-alcoholic fatty liver disease [73], premature puberty [74], kidney disease [75], T1…”
BackgroundInfluentialMetformin Decreases Intracellular Production of Reactive Oxygen Species in Aortic Endothelial Cells
Ouslimani, N., Peynet, J., Bonnefont-Rousselot, D., Thérond, P., Legrand, A., & Beaudeux, J.-L. (2005) · Metabolism · doi:10.1016/j.metabol.2005.01.029 · Cited by 204 · cited 1×
“These results are in line with those of other studies showing that metformin exerts antioxidant effects by decreasing ROS from different sources, including mitochondria and NADPH oxidase in aortic endothelial cells [153].”
ResultBhansali, S., Bhansali, A., Walia, R., Saikia, U. N., & Dhawan, V. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00347 · Cited by 134 · cited 1×
“An “adaptive” increase in mitophagy may delay the progression to T2D by preserving β-cell function in subjects with prediabetes, a prolonged pathogenic phase that lasts for 7–10 years [9].”
BackgroundEscribano-Lopez, I., Diaz-Morales, N., Iannantuoni, F., Lopez-Domenech, S., de Marañon, A. M., Abad-Jimenez, Z., Bañuls, C., Rovira-Llopis, S., Herance, J. R., Rocha, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34251-8 · Cited by 71
Self-citationGhosh, S., Lakshmanan, A. P., Hwang, M. J., Kubba, H., Mushannen, A., Triggle, C. R., & Ding, H. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.10.008 · Cited by 45 · cited 4×
“In line with this idea, Fayyaz et al. demonstrated that palmitate can be metabolized into sphingosine 1-phosphate (S1P) by hepatocytes, which impairs insulin signalling by attenuating insulindependent protein kinase B (Akt) phosphorylation [28].”
BackgroundInfluentialNHX-5, an endosomal Na+/H+ exchanger, is associated with metformin action
Kim, J., Lee, H.-Y., Ahn, J., Hyun, M., Lee, I., Min, K.-J., & You, Y.-J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.c116.744037 · Cited by 25
Cited by
Redox regulation: mechanisms, biology and therapeutic targets in diseases
Li, B., Ming, H., Qin, S., Nice, E. C., Dong, J., Du, Z., & Huang, C. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02095-6 · Cited by 317
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Lima, J. E. B. F., Moreira, N. C. S., & Sakamoto-Hojo, E. T. (2022) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2021.503437 · Cited by 203
Hansel, C., Barr, S., Schemann, A. V., Lauber, K., Hess, J., Unger, K., Zitzelsberger, H., Jendrossek, V., & Klein, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137064 · Cited by 33
“With respect to the vascular compartment, metformin treatment was even shown to exert anti-inflammatory and antioxidant effects [37,38].”
Background
Metadata
- Authors
- Apostolova, N., Iannantuoni, F., Gruevska, A., Muntane, J., Rocha, M., & Victor, V. M.
- Venue
- Redox Biology
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 34
- Pages
- 101517
- ISSN
- 2213-2317 (ISSN-L)
- OpenAlex
- W3028071487
- Cited by
- 197
- References
- 59
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.